Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...

Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports. A number of ...

Devices boosts financial stability with a $70M desktop sale. Read why I'm taking my bearish view off the table for now on ...

Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...

Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Benjamin J. Hindson, the See Remarks of $TXG, sold 4,573 shares of the company on 02-24-2025 for an estimated $50,602. We received data on the trade from a recent SEC ...

ALAN MATEO, a director at $TXG, bought 40,000 shares of the company on 02-21-2025 for an estimated $445,572. This trade was reported by Quiver Quantitative using data ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...